3 terminated. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 3 |
| Phase 2 | 2 | Terminated 2 |
Follow Deafness: new trials by email Literature Review of Deafness trials Research Report on Deafness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
| Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 7 | 2021-12-08 | 2024-07-12 |
| Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment AM-111 0.4 mg/ml, AM-111 0.8 mg/ml, Placebo - Hearing Loss, Idiopathic Sudden Sensorineural | Phase 3 | Terminated | Auris Medical, Inc. | 56 | 2016-06-01 | 2020-08-07 |
Eye Abnormalities (2) · Eye Diseases (2) · Eye Diseases, Hereditary (2) · Retinal Diseases (2) · Retinitis Pigmentosa (2) · Usher Syndromes (2) · Vision Disorders (2) · Ear Diseases (1) · Hearing Disorders (1) · Hearing Loss (1) · Hearing Loss, Sensorineural (1) · Hearing Loss, Unilateral (1) · Nervous System Diseases (1) · Neurologic Manifestations (1)
Pathological Conditions, Signs and Symptoms (3) · Abnormalities, Multiple (2) · Blindness (2) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Deaf-Blind Disorders (2) · Ear Diseases (2) · Genetic Diseases, Inborn (2) · Hearing Disorders (2) · Hearing Loss (2) · Hearing Loss, Sensorineural (2) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Otorhinolaryngologic Diseases (2)
Intravitreal Injections (2) · D-JNKI-1 (1)
Laboratoires Thea (2) · Auris Medical, Inc. (1)
United States (3) · United Kingdom (2) · Canada (1) · Germany (1) · Netherlands (1) · South Korea (1)
Thomas Meier (1)